Bioidentical Hormone Pellets: What the Science Actually Says About Safety
A clinician’s honest, evidence-informed guide for women navigating midlife hormone care at Lumineux Health.
Bioidentical hormone pellets have become one of the most talked-about options in midlife hormone care — and also one of the most misunderstood. If you have found yourself searching for answers late at night, sifting through conflicting headlines about hormone therapy, you are not alone. And your questions about safety are not only valid — they are essential.
This post is not a sales pitch. It is an honest, clinically grounded look at what the evidence actually shows about the safety of bioidentical hormone pellet therapy. Over forty years of research supports the foundational principles behind pellet-based hormone delivery, and recent data — including one of the largest retrospective studies ever conducted and a landmark FDA regulatory decision — have added meaningful clarity to the conversation. Let us walk through it together.
What Are Bioidentical Hormone Pellets?
Bioidentical hormones are chemically identical to the hormones your body produces naturally — specifically estradiol and testosterone. Rather than being synthesized from equine sources (as with some conventional therapies), bioidentical hormones are derived from plant sterols found in wild yam and soy, then compounded into tiny pellets smaller than a grain of rice.
These pellets are placed subcutaneously — just beneath the skin of the upper hip or buttock — during a brief, well-tolerated in-office procedure that takes only a few minutes. Once in place, they release hormones steadily over three to six months: typically three to four months for women, and five to six months for men.
What makes pellet therapy distinctive is its delivery profile. Unlike oral medications that produce daily peaks and troughs, or topical preparations that can vary with absorption, pellets provide consistent, physiologic delivery — mimicking the body’s own steady-state hormone release. For many patients, this translates to more stable symptom relief and fewer fluctuations in mood and energy.
What Does the Safety Data Show?
Safety is the question that matters most, and it deserves a thorough answer. Below is a summary of key evidence points drawn from recent peer-reviewed literature and regulatory developments.
Procedural complication rates are very low.
In 2021, Donovitz published the largest retrospective analysis of testosterone and estradiol pellet implants ever conducted, encompassing over one million insertion procedures. The overall complication rate was less than one percent. Pellet extrusion — one of the most commonly cited concerns — occurred in fewer than one percent of women. Perhaps most tellingly, the continuation rate after two insertions was 93%, suggesting that the vast majority of patients found the therapy both tolerable and beneficial enough to continue. 1
Symptom improvement without increased adverse events.
A 2025 retrospective cohort study by Bailey and Rothenberger compared subcutaneous pellet hormone replacement therapy to transdermal delivery in 404 women. Women receiving pellets experienced significantly greater improvement in hot flashes and all other menopausal symptoms measured — with the exception of depression — and there was no difference in adverse event rates between the two groups. In other words, the pellet group achieved superior symptom relief without paying a safety penalty.2
Cardiovascular safety.
Cardiovascular risk is one of the most frequently raised concerns in any conversation about hormone therapy. A 2023 review by Tostes and Renke examined the cardiovascular safety of subcutaneous testosterone therapy in postmenopausal women across multiple delivery routes — pellet, patch, gel, and spray. The available data showed no evidence that testosterone treatment at physiological or slightly above-physiological levels increases adverse cardiovascular effects. Studies consistently demonstrated no worsening in lipid levels, C-reactive protein, glycated hemoglobin, or insulin sensitivity.3
Breast cancer considerations.
Breast cancer risk is understandably one of the most carefully scrutinized areas of hormone therapy safety. In a 2021 retrospective study of 2,377 postmenopausal women followed over nine years, Donovitz and Cotten found that subcutaneous testosterone — alone or combined with estradiol — significantly reduced breast cancer incidence. The rate in the testosterone-pellet group was 144 per 100,000 patient-years, compared to the SEER age-specific rate of 223 per 100,000 and the Women’s Health Initiative placebo arm rate of 330 per 100,000.4 It is also worth noting that estrogen-only hormone replacement therapy has not been linked to increased breast cancer risk — a finding consistently supported by Women’s Health Initiative data, expert guidance from Breastcancer.org, and updated FDA labeling for HRT products.9 The addition of testosterone may confer additional protective benefit, though ongoing research continues to clarify the magnitude and mechanisms involved. 7
FDA black box warning removal (November 2025).
In a landmark regulatory action in November 2025, the U.S. Department of Health and Human Services and the FDA initiated the removal of broad “black box” warnings from hormone replacement therapy products for menopause. The agency acknowledged that the original warnings were based largely on Women’s Health Initiative data from women who were over a decade past menopause onset, using hormone formulations no longer in common clinical use. This decision represents one of the most significant regulatory shifts in menopause care in over twenty years.6
No adverse changes in lipid profile or glucose metabolism.
A 2022 systematic review and meta-analysis by Liu and colleagues, examining 29 randomized controlled trials encompassing 1,808 women, found that compounded bioidentical hormone therapy was not associated with adverse changes in lipid profile or glucose metabolism. The analysis also reported no change in endometrial thickness and no increase in serious adverse events — further reinforcing the metabolic safety profile of bioidentical hormone preparations.5
Understanding the Nuances: Where Caution Is Still Warranted
Intellectual honesty requires acknowledging what we do not yet know and where important caveats remain. No treatment is universally appropriate, and responsible hormone care demands transparency about limitations.
Compounded pellets are not FDA-approved as individual products. This means that the quality, sterility, and dosing accuracy of pellets can vary across compounding pharmacies. This is precisely why the expertise of your provider — and the rigor of the compounding pharmacy they partner with — matters enormously.
Supraphysiologic dosing — hormone levels climbing above the intended therapeutic range — can occur if therapy is not properly monitored. This is why baseline labs before treatment, four-week post-insertion labs, and regular follow-up appointments are not optional; they are essential safeguards built into responsible clinical practice.
Pellet therapy is not appropriate for all patients. Relative contraindications include active or a history of hormone-sensitive cancers (unless under specific oncologic guidance), untreated uterine hyperplasia, unexplained vaginal bleeding, active liver disease, and a prior venous thromboembolic event without clear etiology. A thorough medical history and individualized risk assessment must precede any treatment decision.
It is also important to understand that once pellets are inserted, they cannot be removed if side effects arise. This is a meaningful difference from transdermal patches or oral medications, which can simply be discontinued. It underscores why getting the dose right — through careful lab monitoring and clinical judgment — is so critical.
These nuances are not reasons to avoid pellet therapy. They are reasons to ensure that your care is guided by a clinician with deep expertise, rigorous monitoring protocols, and a genuine commitment to ongoing communication.8
The Lumineux Approach to Safety
At Lumineux Health, the safety of your hormone care is never an afterthought — it is the architecture upon which everything else is built.
Every patient begins with a comprehensive evaluation: a detailed medical history, a thorough examination, and an individualized laboratory panel designed to establish your unique hormonal baseline. We do not guess. We measure.
Following your first pellet insertion, we obtain labs at four weeks to assess your response and calibrate dosing for subsequent treatments. Ongoing symptom monitoring and laboratory review continue throughout your care, ensuring that your therapy remains precisely tailored to your evolving needs.
With Dr. Amanda Vaughan, FACOG, you have direct access to a board-certified physician who specializes in hormone health — not a rushed visit with a provider who is seeing you for the first time. There is no one-size-fits-all dosing at Lumineux. Every decision is made through transparent, shared decision-making about benefits, risks, and alternatives — because your trust and safety are the foundation of everything we do.
Choosing hormone therapy is a deeply personal decision, and it deserves to be guided by evidence, expertise, and a clinician who takes the time to listen. The science behind bioidentical hormone pellets continues to grow, and for many women, it offers a compelling path toward feeling like themselves again.
If you are ready to have an honest, informed conversation about your hormonal health — one grounded in data and tailored to your life — we would be glad to begin that journey with you.
Schedule a consultation with Dr. Vaughan at Lumineux Health.
References
1. Donovitz GS. Low complication rates of testosterone and estradiol implants for androgen and estrogen replacement therapy in over 1 million procedures. Therapeutic Advances in Endocrinology and Metabolism. 2021;12:20420188211015238. https://pmc.ncbi.nlm.nih.gov/articles/PMC8165877/
2. Bailey G, Rothenberger RW. Comparison of Two Delivery Methods of Bioidentical Hormone Replacement Therapy. NAPGO. 2025. https://www.napgo.org/article/147434-comparison-of-two-delivery-methods-of-bioidentical-hormone-r eplacement-therapy
3. Tostes F, Renke G. Cardiovascular Safety and Benefits of Testosterone Implant Therapy in Postmenopausal Women: Where Are We? Pharmaceuticals. 2023;16(4):619. https://pmc.ncbi.nlm.nih.gov/articles/PMC10146246/
4. Donovitz GS, Cotten M. Breast Cancer Incidence Reduction in Women Treated with Subcutaneous Testosterone: Testosterone Therapy and Breast Cancer Incidence Study. European Journal of Breast Health. 2021;17(2):150–156. https://pmc.ncbi.nlm.nih.gov/articles/PMC8025725/
5. Liu Y, Yuan Y, Day AJ, et al. Safety and efficacy of compounded bioidentical hormone therapy (cBHT) in perimenopausal and postmenopausal women: a systematic review and meta-analysis of randomized controlled trials. Menopause. 2022;29(4):466–483. https://journals.lww.com/10.1097/GME.0000000000001937
6. U.S. Department of Health and Human Services (HHS). HHS Advances Women’s Health, Removes Misleading FDA Warnings on Hormone Replacement Therapy. FDA Press Announcement. November 10, 2025. https://www.fda.gov/ne ws-events/press-announcements/hhs-advances-womens-health-removes-misleading-fda-warnings-hormone-replaceme nt-therapy
7. Dimitrakakis C, Glaser R. Testosterone Implant Therapy in Women With and Without Breast Cancer: Rationale, Experience, Evidence. Androgens: Clinical Research and Therapeutics. 2021;2(1):120–130. https://www.liebertpub.com/doi/10.1089/andro.2021.0003
8. Dixit A, Carden N, Stephens E, et al. Hormone replacement therapy subcutaneous implants for refractory menopause symptoms; the patient’s perspective. Women’s Health. 2022;18. https://journals.sagepub.com/doi/10.1177/20533691221097042
9. Hormone Replacement Therapy (HRT) and Breast Cancer Risk. Breastcancer.org. Updated January 2026. https://www.breastcancer.org/risk/risk-factors/using-hormone-replacement-therapy
